Fubotv earnings beat by $0.10, revenue topped estimates
Louise Frederika Kooij, the Chief Accounting Officer of NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS), recently executed a significant stock transaction. According to a recent SEC filing, Kooij sold 150,000 ordinary shares of the company on March 4, 2025, at a price of $20.37 per share, resulting in a total transaction value of approximately $3.06 million. The stock has shown remarkable strength recently, with a 17% gain in the past week and 42% over six months, according to InvestingPro data.
The sale occurred after Kooij exercised options to acquire 150,000 ordinary shares at a nominal exercise price. Following these transactions, Kooij holds 15,000 shares directly. The options were originally granted as part of a replacement agreement due to a prior business combination involving NewAmsterdam Pharma. The company maintains a strong financial position with more cash than debt and a healthy current ratio of 8.08, indicating robust liquidity.
These transactions reflect Kooij’s active management of her equity holdings in the company, which specializes in pharmaceutical preparations. With a market capitalization of $2.53 billion and impressive revenue growth of 223% in the last twelve months, NewAmsterdam Pharma presents an interesting case for investors. For comprehensive analysis and 12 additional exclusive insights, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, NewAmsterdam Pharma reported a strong financial position with an unaudited cash balance of $835 million, following a successful public offering in December 2024. The company is preparing for global regulatory submissions of its cholesterol-lowering drug candidate, obicetrapib, after positive results from three Phase 3 trials. These trials demonstrated significant reductions in LDL-C levels and major adverse cardiovascular events (MACE), with the BROADWAY trial showing a 21% reduction in MACE. Scotiabank (TSX:BNS) has raised its price target for NewAmsterdam Pharma to $52, citing the robust clinical data and solid financial health as factors that could position the company for a potential acquisition. H.C. Wainwright also initiated coverage on the company with a Buy rating, highlighting the potential of obicetrapib to become a preferred treatment for patients not achieving cholesterol goals with statins. Additionally, NewAmsterdam Pharma has halted its $150 million share sale plan, terminating its Automatic Teller Machine (ATM) Prospectus. The decision to suspend the share sale was communicated to Cowen and Company, LLC, and TD Securities (USA) LLC, although the company has not disclosed specific reasons for the suspension. These developments reflect NewAmsterdam Pharma’s strategic focus on advancing obicetrapib toward commercialization while maintaining financial stability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.